Cicletanine: New insights into its pharmacological actions

General Pharmacology

Volumn 33, Issue 1, 1999, Pages 7-16

  Kalinowski, Leszek ^a   Szczepańska Konkel, Mirosława ^a   Jankowski, Maciej ^a   Angielski, Stefan ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Adrenergic response; Antihypertensive effect; Cicletanine; Cyclic GMP phosphodiesterase; Cytoprotective effect; K+ channel; Kidney; Natriuresis; Prostacyclin synthesis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; ARACHIDONIC ACID; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL; CICLETANINE; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYTOSKELETON PROTEIN; DEOXYCORTICOSTERONE ACETATE; ICOSANOID; INDOMETACIN; MECLOFENAMIC ACID; MUSCARINIC RECEPTOR; MYOSIN LIGHT CHAIN KINASE; NEUROTRANSMITTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENTOLAMINE; POTASSIUM CHANNEL; PROSTACYCLIN; PROSTAGLANDIN; PROTEIN KINASE C; VASOPRESSIN; ZAPRINAST;

BLOOD VESSEL REACTIVITY; CELL PROTECTION; DOG; DRUG ACTIVITY; DRUG MECHANISM; GUINEA PIG; HEART PROTECTION; HUMAN; HYPERTENSION; MOUSE; NATRIURESIS; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RABBIT; RAT; REVIEW; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; PYRIDINES;

EID: 0345120852     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00257-2     Document Type: Review

References (67)

1. Alvarez-Guerra, M., Alda, O., Morin, E., Allard, M., Garay, R.P., 1996. Reduction by (-)-cicletanine of the vascular reactivity to angiotensin II in rats. J Cardiovasc Pharmac 28, 564-570.
2. Auguet, M., Delaflotte, S., Hellegouarch, A., Guillon, J.M., Baranés, J., Pirotzky, E., Clostre, F., Braquet, P., 1988. In vitro cardiovascular antihistamine properties of cicletanine in comparison with diphenhydramine. Drugs Exp Clin Res 14, 149-153.
3. Buchholz, R.A., Brousseau, A., Silver, P.J., 1992. Natriuretic and diuretic effects of cicletanine in conscious, hydrated, normotensive rats. Drugs Dev Res 25, 125-137.
4. Bukoski, R.D., Wagman, D.W., De Wan, P., Xue, H., 1989. Vascular actions of cicletanine. Arch Mal Coeur 82, 45-50.
5. Bukoski, R.D., Bo, J., Xue, H., Bian, K., 1993. Antiproliferative and endothelium-dependent vasodilator properties of 1,3-dihydro-3-p-chlorophenyl-7-hydroxy-6-methyl-furo-(3,4c) pyridine hydrochloride (cicletanine). J Pharmac Exp Ther 265, 30-35.
6. Calder, J.A., 1992. Mechanism of antihypertensive action of thiazide diuretics and related drugs: direct vascular effects. J Drug Dev 4, 189-198.
7. Calder, J.A., Schachter, M., Sever, P.S., 1992a. Mechanisms of action of cicletanine in human and guinea pig resistance arteries. J Cardiovasc Pharmac 19, 387-393.
8. Calder, J.A., Schachter, M., Sever, P.S., 1992b. Interaction between cicletanine and the eicosanoid system in human subcutaneous resistance arteries. J Pharm Pharmac 44, 574-578.
9. Calder, J.A., Schachter, M., Sever, P.S., 1994. Potassium channel opening properties of thiazide diuretics in isolated guinea pig resistance arteries. J Cardiovasc Pharmac 24, 158-164.
10. Castro, A., Florentino, A., Fuentes, J.A., 1988. Antihypertensive effect of non-diuretic doses of cicletanine on a stress-induced model in the rat. Drugs Exp Clin Res 14, 97-101.
11. Castro, A., Parra, L., Fuentes, J.A., 1989. Studies on the mechanism of action of the antihypertensive agent cicletanine. Arch Mal Coeur 82, 51-54.
12. Castro, A., Parra, L., Alsasua, A., Fuentes, J.A., 1990. The anithypertensive agent cicletanine reverses vascular hyperractivity to noradrenaline and cardiac hyperthrophy in DOCA-salt rats. Arch Int Pharmacodyn Ther 307, 109-18.
13. Castro, A., Hernando, F., Parra, L., Puerro, M., Aleixandre, A., Fuentes, J.A., 1995. Further evidence for a peripheral sympathicolytic action of the antihypertensive cicletanine rats. Drugs Exp Clin Res 21, 29-36.
14. Chabrier, P.E., Guinot, P., Tarrade, T., Auguet, M., Cabanie, M., Clostre, F., Etienne, A., Esanu, A., Graquet, P., 1988. Cicletanine. Cardiovasc Drug Rev 6, 166-179.
15. Damase-Michel, C., Girolami, J.P., Bascands, J.L., Tran, M.A., Moatti, J.P., Pecher, C., Berthet, P., Tarrade, T., Montastruc, J.L., 1991. Effects of cicletanine on vasoactive systems in consious sinoartic-denervated dogs. Fund Clin Pharmac 5, 719-732.
16. Deby, C., Bourgain, R.H., Andries, R., Braquet, P., 1988a. Modulation of prostacyclin synthetase by cicletanine and drugs which affect ion transport. Pharmac Res Commun 20, 101-108.
17. Deby, C., Bourgain, R.H., Deby Dupont, G., Pincemail, J., Garay, R., Braquet, P., 1988b. Modulation of in vivo generation of prostanoids by drugs affecting membrane ion transport. Drugs Exp Clin Res 14, 123-134.
18. Deitmer, P., Golenhofen, K., Noack, T., 1992. Comparison of the relaxing effects of cicletanine and cromacalim on vascular smooth muscle. J Cardiovasc Pharmac 20, 35-42.
19. Ebeigbe, A.B., Cabanié, M., 1991. In vitro effects of cicletanine in pregnancy induced hypertension. Br J Pharmac 103, 1992-1996.
20. Ebeigbe, A.B., Cabanié, M., Godfraind, T., 1989. Effects of cicletanine on histamine-induced contractions of isolated rabbit mesenteric arteries. Fund Clin Pharmac 3, 223-235.
21. Ebeigbe, A.B., Oguogho, A., Ighoroje, A.D.A., Aloamaka, C.P., 1994. Differential effects of prostanoid synthesis inhibitors on cicletanine-induced relaxation of isolated human epigastric arteries. Clin Auton Res 4, 137-139.
22. Edwards, G., Weston, A.H., 1990. Potassium channel openers. In: Barber, M.S. (Ed.), Pharmaceutical manufacturing international. Sterling Publications, London, pp. 29-32.
23. Emond, C., Bompart, G., Rakotoarivony, J., Bascands, J.L., Pecher, C., Adam, A., Tarrade, T., Berthet, P., Girolami, J.P., 1992. Protective effect of cicletanine on hypertension-induced decreases in the renal kallikrein-kinin and prostaglandin systems in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmac 20, 601-608.
24. Esanu, A., 1986. Dossier d'autorisation de mise sur le marché (A.M.M.). Cicletanine. Dossier no. 328747.9 (27.7.1986). Société de Conceil de Recherches et d'Applications Scientifiques BE 891.797; DE 3.204.596; FR 2.449.406 and 2.499.574; GB 2.092.586; JP 82.150.688; US 4.483.998.
25. Ferdinandy, P., Koltai, M., Tosaki, A., Berthet, P., Tarrade, T., Esanu, A. Braquet, P., 1992. Cicletanine improves myocardial function deteriorated by ischemia/reperfusion in isolated working rat hearts. J Cardiovasc Pharmac 19, 181-189.
26. ATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide. Cardiovasc Res 30, 781-787.
27. Garay, R.P., Rosati, C., Nazaret, A., Esanu, T., Tarrade, T., Braquet, P., 1992. Cicletanine sulfate: inhibition of anion transport systems and natriuretic activity. Naunyn-Schmiedenberg's Arch Pharmac 346, 114-119.
28. Garay, R.P., Rosati, C., Fanous, K., Allard, M., Morin, E., Lamiable, D., Vistelle, R., 1995. Evidence for (+)-cicletanine sulfate as an active natriuretic metabolite of cicletanine in the rat. Eur J Pharmac 274, 175-180.
29. Gerber, J.G., Olson, R.D., Nies, A.S., 1981. Interrelationship between prostaglandins and renin release. Kidney Int 19, 816-821.
30. Greven, J., 1995. Effects of cicletanine on kidney function: 1. Clearance and micropuncture studies in anesthetized rats. J Pharmac Exp Ther 273, 1190-1196.
31. Greven, J., Rahn, A., Brändle, E., 1995. Effects of cicletanine on kidney function: 2. Role of renal prostaglandins and kinins, and of muscarinic receptors. J Pharmac Exp Ther 273, 1197-1202.
32. Hadj-Aissa, A., Pozet, H., Labetin, M., Zech, P., 1987. Site of renal action of cicletanine in man. In: Puschett, S.B., Greenberg, A. (Eds.), Diuretics II: chemistry, pharmacology and clinical applications. Elsevier, New York, pp. 35-37.
33. Hajjar, D.P., Pomerantz, K.B., 1989. Cicletanine stimulates cholesteryl ester hydrolase activities and prostacyclin production in arterial smooth muscle cells. Arch Mal Coeur 82, 79-84.
34. Hirawa, N., Uehara, Y., Kawabata, Y., Akie, Y., Ichikawa, A., Funahashi, N., Goto, A., Omata, M., 1996. Restoration of endothelial cell function by chronic cicletanine treatment in Dahl salt-sensitive rats with salt-induced hypertension. Hypertens Res 19, 263-270.
35. Jouve, R., Langlet, F., Puddu, P.E., Rolland, P.H., Guillen, J.C., Cano, J.P., Serradimigni, A., 1986. Cicletanine improves outcome after left circumflex coronary artery occlusion-reperfusion in the dog. J Cardiovasc Pharmac 8, 208-215.
36. Jouve, R., Puddu, P.E., Langlet, F., Lanti, M., Guillen, J.C., Rolland, P.H., Serradimigni, A., 1988. Effects of cicletanine in the left circumflex coronary artery occlusion-reperfusion canine model of sudden death: analysis of 107 experiments using Cox's proportional hazard models. Drugs Exp Clin Res 14, 167-180.
37. Kalinowski, L., Szczepańska-Konkel, M., Pawełczyk, T., Bizon, D., Angielski, S., 1995. Inhibition of cGMP-phosphodiesterase restores the glomerular effects of atrial natriuretic factor in low sodium diet rats. Renal Physiol Biochem 18, 254-266.
38. Kalinowski, L., Szczepańska-Konkel, M., Jankowski, M., Angielski, S., 1997. Modulation by low sodium intake of glomerular response to cicletanine and atrial natriuretic factor. Br J Pharmac 121, 635-642.
39. Koltai, M., Esanu, A., Braquet, P., 1990. Relaxation of vascular smooth muscle by cicletanine: importance of potassium channels and prostacyclin. In: Frölich, J.C., Förstermann, U. (Eds.), Klinische pharmakologie [Clinical Pharmacology, Vol. 7: Importance of prostacyclin and potassium channels for the regulation of vascular tone]. W. Zuckschwerdt Verlag, Munich, pp. 106-136.
40. Koltai, M., Tosaki, A., Tarrade, T., Berthet, P., Esanu, A., Braquet, P.G., 1991. Cicletanine: a novel approach to cardioprotection in spontaneously hypertensive rats. Coronary Artery Dis 2, 941-994.
41. Koltai, M., Tosaki, A., Berthet, P., Tarrade, T., Braquet, P.G., 1992. Effect of cicletanine on reperfusion-induced arrhythmias and myocardial ion contents: a comparison with furosemide. Eur Heart J 13, 395-403.
42. m cGMP phosphodiesterase inhibitors cicletanine and zaprinast in anesthethized dogs. Drug Dev Res 23, 127-144.
43. Lehoux, S., Plante, G.E., 1995. Antihypertensive drugs and endothelial cell function. Prostaglandins Leukot Essent Fatty Acids 54, 65-70.
44. 1-receptors mediate phosphoinositide and calcium response in cultured smooth muscle cells: interaction with cicletanine. Agents Actions 24, 255-260.
45. Malhebre, E., Le Hegara, M., Clostre, F., Braquet, P., 1988. Comparison of cicletanine with other antihypertensive drugs in SHR-SP models. Drugs Exp Clin Res 14, 83-88.
46. Mikkelsen, E.O., Sehested, J., Poulsen, S.H., 1993. Comparison of in vitro effects of cicletanine, its enantiomers and major metabolite on rat thoracic aorta. Naunyn-Schmiedeberg's Arch Pharmac 347, 548-552.
47. Miller, M., Weston, A.H., 1991. Studies on the mode of action of cicletanine in rat blood vessels. Fund Clin Pharmac 5, 408.
48. Noack, T., Deitmer, P., 1993. Effects of cicletanine on whole-cell currents of single smooth muscle cells from the guinea-pig portal vein. Br J Pharmac 109, 164-170.
49. Roesler, J.M., McCafferty, J.P., DeMarinis, R.M., Matthewa, W.D., Hieble, J.P., 1986. Characterization of the antihypertensive activity of SK&F 86466, a selective alpha-2 antagonist, in the rat. J Pharmac Exp Ther 236, 1-7.
50. 1 antagonistic effect of cicletanine in guinea pig isolated ileum. Eur J Pharmac 136, 235-238.
51. Shenker, Y., 1988. Atrial natriuretic hormone effect on renal function and aldosterone secretion in sodium depletion. Am J Physiol 255, R867-R873.
52. + channel opening and vascular tone. In: Mulvany, M.J., Aalkjaer, C., Heagerty, A.M., Nyborg, N.C.B., Strangaard, S. (Eds.), Resistance arteries: structure and function. Elsevier, Amsterdam, pp. 130-138.
53. Silver, P.J., Cumiskey, W.R., 1991. Uptake of cicletanine by vascular smooth muscle. Drug Dev Res 23, 275-280.
54. m cyclic GMP phosphodiesterases and potentiation of guanylate cyclase activators by cicletanine. J Cardiovasc Pharmac 16, 501-505.
55. ++-regulated protein kinases and relationship to vasorelaxation by cicletanine. J Pharmac Exp Ther 257, 382-391.
56. Singer, D.R.J., Markandu, N.D., Sugden, A.L., MacGregor, G.A., 1990. A comparison of the acute effects of cicletanine and bendrofluazide on urinary electrolytes and plasma potassium in essential hypertension. Eur J Clin Pharmac 39, 227-232.
57. + channels are responsible for angiotensin II hypersensitive contraction and atrial natriuretic factor refractoriness of glomeruli in low-sodium rats. Biochem Biophys Res Commun 181, 871-876.
58. Szilvássy, Z., Jakab, I., Bor, P., Koltai, M., Tarrade, T., Esanu, A., Braquet, P., Lonovics, J., 1993. Cicletanine attenuates overdrive pacing-induced global myocardial ischemia in rabbits: possible role of cardiac cyclic nucleotides. Coronary Artery Dis 4, 443-452.
59. Tarrade, T., Guinot, P., 1988. Efficacy and tolerance of cicletanine, a new antihypertensive agent: overview of 1226 treated patients. Drugs Exp Clin Res 14, 205-214.
60. ++) induced by ischemia/reperfusion in isolated rat heart? J Cardiovasc Pharmac 17, 551-559.
61. Trapani, A.J., Smits, G.J., McGraw, D.E., McMahon, E.G., Blaine, E.H., 1991. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor. J Pharmac Exp Ther 258, 269-274.
62. Uehara, Y., Numabe, A., Hirawa, N., Kawabata, Y., Iwai, J., Ono, H., Matsuoka, H., Takabatake, Y., Yagi, S., Sugimoto, T., 1991a. Antihypertensive effects of cicletanine and renal protection in Dahl salt-sensitive rats. J Hypertens 9, 719-728.
63. Uehara, Y., Numabe, A., Kawabata, Y., Nagata, T., Iwai, J., Matsuoka, H., Yagi, S., Takabatake, Y., Sugimoto, T., 1991b. Evidence for medial-mass regression in the vascular wall of Dahl hypertensive rats by cicletanine treatment. J Cardiovasc Pharmac 18, 158-166.
64. Uehara, Y., Kawabata, Y., Hirawa, N., Takada, S., Nagata, T., Numabe, A., Iwai, J., Sugimoto, T., 1993. Possible radical scavenging properties of cicletanine and renal protection in Dahl salt sensitive rats. Am J Hypertens 6, 463-472.
65. Uehara, Y., Hirawa, Y., Kawabata, Y., Akie, Y., Ichikawa, A., Funahashi, N., Goto, A., Omata, M., 1997. Lipid metabolism and renal protection by chronic cicletanine treatment in Dahl salt-sensitive rats with salt-induced hypertension. Blood Press 6, 180-187.
66. Vargas, F., Alvarez-Guerra, M., Droy-Lefaix, M.T., Garay, R.P., 1998. Inhibition by (-)-cicletanine of the vascular reactivity to angiotensin II and vasopressin in isolated rat vessels. Am J Hypertens 11, 579-584.
67. Vistelle, R., Lamiable, D., Morin, E., Trenque, T., Kaltenbach, M., 1995. Urinary excretion of cicletanine in the rat: stereochemical aspects. Drug Metab Dispos 23, 988-992.